{"name":"Immunocore Holdings","slug":"immunocore","ticker":"IMCR","exchange":"NASDAQ","domain":"immunocore.com","description":"Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase ","hq":"Abingdon, Oxfordshire, UK","founded":0,"employees":"524","ceo":"Bahija Jallal","sector":"Immuno-Oncology / TCR Bispecifics","stockPrice":32.49,"stockChange":0.53,"stockChangePercent":1.66,"marketCap":"$1.6B","metrics":{"revenue":260000000,"revenueGrowth":24.3,"grossMargin":96.5,"rdSpend":274869000,"netIncome":-35514000,"cash":864153024,"dividendYield":0,"peRatio":-23,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Tiragolumab patent cliff ($1.5B at risk)","drug":"Tiragolumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Immunocore Holdings Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Immunocore Holdings reported its fourth quarter and full year 2023 financial results, with a net loss of $1.1 billion and $3.5 billion, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Immunocore Holdings Announces Collaboration with Merck KGaA to Develop TCR Bispecific Therapies","summary":"Immunocore Holdings announced a collaboration with Merck KGaA to develop TCR bispecific therapies for the treatment of various cancers.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Immunocore Holdings Announces Positive Interim Results from Phase 2 Clinical Trial of Tiragolumab in Non-Small Cell Lung Cancer","summary":"Immunocore Holdings announced positive interim results from a Phase 2 clinical trial of tiragolumab in non-small cell lung cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Assessing Immunocore Holdings (IMCR) Valuation After Analyst Downgrade And Pipeline Timing Shift - simplywall.st","headline":"Assessing Immunocore Holdings (IMCR) Valuation After Analyst Downgrade And Pipeline Timing Shift","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals - simplywall.st","headline":"Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxORjEwZDVYSXpCZXY3cV9ReVVKUWFzR0ctc3JNY3BpQTFaNUg4Y3BhVXRqWVBtS01URE95R0xLcFoxM0tHRzdvMy1GQUU4U2M2dHNvaUh2Qy1UQjJac3o0QzhueWJ5YWlwRUJSdTVaWVN0bFhTdU9Yd096LWFlVkdBUW5nQU5OTHBQaWJFb0Z2SFFzWXRlbVVzakFDRzIwWmhTNFlV?oc=5","date":"2026-02-25","type":"pipeline","source":"TradingView","summary":"Immunocore Holdings plc SEC 10-K Report - TradingView","headline":"Immunocore Holdings plc SEC 10-K Report","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQNW5Ka2NicjBvXzFSZWd1dEJWZWh1eVNMaUN2SHpRUEp3OE1uaDBOQXMybi1CamR6VmN5aHpyeXBLRzlDOEFyZ3lhWXo5Y2pNSUN2VXBydkxlQ1ZIeV8tcEZObmtiZ21Jc2d0WU9WWGN5V1NRWW52QUZMcklTYUhrXzY3X1pQU05vSnI3YlFRbGg2d0NPcmRLMWJra0Z4Y2c?oc=5","date":"2026-02-20","type":"earnings","source":"Finviz","summary":"Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz","headline":"Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down","sentiment":"negative"},{"date":"2026-01-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNX0wzNE8xY19sLWllRVpkUmJtc1BpM2R5eUFZU0lJbmgxZHRnN184dnVJdGRTSU85ZTdDM3pacmNvNmRXVF9ETmZMdlk2MEl0SVlfM2FxVEFIcnlhclZMakk5VmJrUjA5S0YtUm16bU9vMk1VcFdnQWRabzJhenlKd1I3LXZzU2J6d0t4NjliM0sxSzg3RjNkUnB0ZmdhbjhGbTAxeTBUY01jdXpOanpaSjFqMV8zTDFGczgyZHh3N2EtcGE5dGc1T05iRHZObzlteXd3eUU5Z0Z1T0xFdElNSE9rLV9nZlNT0gHuAUFVX3lxTE5YaHVKVmVKRTFSVUhsb09tLU9WLU0yTzdrSTZLa0tiZDBzY0k5ZDJQYW5VU3pGSERHS3V6WEVyZlBLRVBBWUt1Wnh6bjdUNGl0V3hINFJZcURqX01CSFByVk1lbEt1dDdKYXQ5UHloSU1rYTBWeFJ1NEc3TXNfejRYQjNPUmxnNkF3a2ZmbVRrS2lDNlExNFdKLThPT1pOWmpXdTBha3FiaTFQMnJUNVQ1X3I4aUhIeXFOQ0tMQ2JVd0V5WnVGaW9oT2lMLUNtZlAwWGFjRUlQclRISEdIOHo1MDdxcUZQWGdRT1ZtRHc?oc=5","date":"2025-08-02","type":"earnings","source":"simplywall.st","summary":"Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry? - simplywall.st","headline":"Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-10","type":"pipeline","source":"simplywall.st","summary":"Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st","headline":"Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNM3BEbVZhbjhqWE0tYWlfTmlsT3pQaE14SC1ZNWY1bG9Jb1Z1cDU3Y0JMTHoxbmFUTlpHWGdUNzJrZ1FuTGtwRWsxUDdNY1FRdW9iOGtrSk1KRTZSVGZKNG9EOVp3aEFXZktVQXhGNS1XUnp0SFExV3ZqMHMzV183STNiZ0RiT1VHazhReTlQQVRyb2N1RXE0?oc=5","date":"2025-02-02","type":"pipeline","source":"entrepreneur.com","summary":"3 Niche Healthcare Stocks Tackling Rare Diseases - entrepreneur.com","headline":"3 Niche Healthcare Stocks Tackling Rare Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQM21OTk1VMGI5enVLaDctNUMxMU5YVUZQYmRhdDRWRXdtWF9SWjBiTmQ3OVpDeHJFVnZJeG9tdXE4SnlPN25VSk1FaG5kalI1MXBFdXFHRloyR3dJdThQX0VyZUJfVjh6ZGluM2pvT0w1dDN4YjMwOXFvX2gxNkVXdVdRVy1RWDctMlFVeWYxc2RMQ1pFU19PdlJNc3ZJQU5CbE51OUR2d0w5emtfYzFmRVVYcE1Wb1ViLXk0?oc=5","date":"2025-01-22","type":"pipeline","source":"TradingView","summary":"3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare - TradingView","headline":"3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQRDYwaHN6dUtLV1VwZmRPNDBybWo4RDJyWkhVNk9ZNnlkVjJXUEs1OWFQSl9VSExjZ1pWSEhoSHFDZkRYbC15N1VRR25tWVE5UFJ5MUEySm5wMkdQWlBUaGRmLXNfVHRJUk9fN1NLMTVETnIyRTBtZzRvdUNsM2xxUE10c3BVd2pWVnhhdDB5eUdJdTFzTHgwbFdoYkVzbnVHOFpjLTlqZkVCUXIyUEFuN2EwX1JIbkwzTHN1U2x0bw?oc=5","date":"2024-08-12","type":"pipeline","source":"Seeking Alpha","summary":"Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal - Seeking Alpha","headline":"Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxOdkhMN0djWXF6dTdPSk9iMkk1YkpkU01RSkVfR1VYWndRSWE4VHk4cDRPNWY3NlhkZ1FTU0RDNE44VVpWY2ZWLW1hU29tMlJ2NEtzN2l1U29UWG52WndoYTlNeU1ydVNXMTFpNUFIRkpjTXM3bVNjanFfRG5EdjB6UkEtTDhqeFUwSnc4RVRwQWdoZzg2WlVxMm0xV21ZMEliSmJmRFpHTUNwSlZTR1pXRy1pUGV0UEdCaGlRS20tbFVDa3JkMTU0WHMyNGowN19CTll2ODVERFptUks5a01WOXJDSlo1UDZFODRVMHhNcjZKZw?oc=5","date":"2022-11-09","type":"pipeline","source":"PR Newswire","summary":"Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America - PR Newswire","headline":"Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America","sentiment":"neutral"}],"patents":[{"drugName":"Tiragolumab","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-Oncology","TCR Bispecifics"],"financials":{"source":"sec_edgar+yahoo","revenue":249428000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":249428000,"period":"2023-12-31"},{"value":174361000,"period":"2022-12-31"},{"value":36484000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":274869000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-35514000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1067269000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":524,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":32.49,"previousClose":31.96,"fiftyTwoWeekHigh":40.72,"fiftyTwoWeekLow":23.15,"fiftyTwoWeekRange":"23.15 - 40.715","fiftyDayAverage":31.99,"twoHundredDayAverage":33.76,"beta":0.83,"enterpriseValue":1192748672,"forwardPE":-23,"priceToBook":4.32,"priceToSales":4.12,"enterpriseToRevenue":2.98,"enterpriseToEbitda":-53.34,"pegRatio":0,"ebitda":-22359000,"ebitdaMargin":-5.6,"freeCashflow":23960624,"operatingCashflow":-10712000,"totalDebt":436687008,"debtToEquity":114.6,"currentRatio":4.04,"returnOnAssets":-1.5,"returnOnEquity":-9.6,"analystRating":"","recommendationKey":"none","numberOfAnalysts":13,"targetMeanPrice":63.86,"targetHighPrice":100,"targetLowPrice":33,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":99.2,"sharesOutstanding":50695078,"floatShares":45055758,"sharesShort":10137184,"shortRatio":26.37,"shortPercentOfFloat":20,"epsTrailing":-0.71,"epsForward":-1.41,"revenuePerShare":7.95,"bookValue":7.52,"officers":[{"age":64,"name":"Dr. Bahija  Jallal Ph.D.","title":"CEO & Executive Director"},{"age":45,"name":"Mr. Travis A. Coy M.B.A.","title":"CFO, Executive VP & Head of Corporate Development"},{"age":57,"name":"Ms. Tina St. Leger","title":"Executive VP & Chief Human Resources Officer"},{"age":51,"name":"Mr. John  Trainer M.B.A.","title":"SVP & Chief Operating Officer"},{"age":null,"name":"Mr. John  Goll III","title":"SVP, Finance & Chief Accounting Officer"},{"age":null,"name":"Ms. Annelise  Vuidepot Ph.D.","title":"Senior VP, CTO and Research & UK Site Lead"},{"age":42,"name":"Mr. Sean D. Buckley","title":"VP & Chief Information Officer"},{"age":null,"name":"Mr. Clayton  Robertson","title":"Head of Investor Relations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.immunocore.com","phone":"44 12 3543 8600"}}